Physician profile
Jorge Ortiz
NPI 1083612592
$2,224.12
in general payments reported to CMS, 2019-2025
13 companies · $404 in 2025
The $404 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $111 · 2021: $175 · 2022: $348 · 2023: $373 · 2024: $402 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $472.00 | 2019-2024 | Bexsero, Rotarix, Pediarix |
| Tris Pharma INC | $444.29 | 2019-2025 | Quillichew Er, Onyda Xr, Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $326.36 | 2019-2024 | Jornay Pm |
| Corium, LLC | $192.16 | 2024-2025 | Azstarys |
| Acadia Pharmaceuticals INC | $166.63 | 2023-2024 | Daybue |
| Collegium Pharmaceutical, INC. | $164.94 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $130.92 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $103.98 | 2022-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $88.45 | 2024-2025 | Vaxneuvance, Vaxelis, M-M-R II |
| Vertical Pharmaceuticals, LLC | $56.81 | 2019-2020 | |
| Sanofi Pasteur INC. | $37.68 | 2019-2023 | |
| Seqirus USA INC | $23.73 | 2025 | Flucelvax |
| Cumberland Pharmaceuticals, INC. | $16.17 | 2025 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.